J. Safra Sarasin Holding AG Has $47.48 Million Position in Zoetis Inc. (NYSE:ZTS)

J. Safra Sarasin Holding AG decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 291,430 shares of the company's stock after selling 63,939 shares during the quarter. J. Safra Sarasin Holding AG owned 0.06% of Zoetis worth $47,483,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. Mission Wealth Management LP lifted its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares during the period. VeraBank N.A. grew its holdings in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC grew its position in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Procyon Advisors LLC raised its stake in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after acquiring an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its position in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after purchasing an additional 65 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $214.40.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by insiders.

Zoetis Stock Up 0.7 %

ZTS traded up $1.09 during trading on Wednesday, reaching $151.08. The company had a trading volume of 2,093,141 shares, compared to its average volume of 2,522,363. The company has a market cap of $67.41 billion, a P/E ratio of 27.62, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business's fifty day moving average price is $159.06 and its 200 day moving average price is $169.10.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.32%. Zoetis's payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.